To be clear, I expect Merck to post sales growth, operationally, but that growth will be materially trimmed (by about seven per cent), at the sales line due to a strong US dollar, and weaker euro and Yen primarily. It is just my guess -- but here is the J&J Q3 2015 earnings press releasse -- as filed with the SEC last week:
. . . .[J&J] today announced sales of $17.1 billion for the third quarter of 2015, a decrease of 7.4% as compared to the third quarter of 2014. Operational sales results increased 0.8% and the negative impact of currency was 8.2%. Domestic sales decreased 0.6%. International sales decreased 13.7%, reflecting operational growth of 2.1% and a negative currency impact of 15.8%. . . .
So -- have a great evening, one and all -- I'll cover any surprises, mañana!
2 comments:
Well -- currencies were a per cent worse than I guessed, and sales were a slight miss, but with a five penny "beat" at the EPS line, and a bumped up full year forecast. . . Merck looks to be in pretty good shape.
Namaste, all -- and good morning!
Agree that it was a pretty good report for MRK.
Post a Comment